ClinicalTrials.gg

Program

Letrozole

Also written as “letrozole”, “Letrozole Tablets 2.5 mg” and “Arm C: Gedatolisib + Palbociclib + Letrozole”.

Its studies are mostly in Breast Neoplasms · Neoplasms · Polycystic Ovary Syndrome · Endometrial Neoplasms · Infertility, led by 7 companies.

Furthest: phase 4, since Apr 10, 200138 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis280 open or runningphase 4since Apr 10, 2001Apr 10, 2001none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Jun 13, 2011Jun 13, 2011none ahead
Egymedicalpedia21 open or runningphase 1since Apr 9, 2024Apr 9, 2024none ahead
Hikma Pharmaceuticals20 open or runningphase 1since Jun 3, 2011Jun 3, 2011none ahead
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
rovi-pharmaceuticals-laboratories10 open or runningphase 1since Jan 8, 2018Jan 8, 2018none ahead
Sun Pharmaceutical Industries10 open or runningphase 3since Jan 24, 2008Jan 24, 2008none ahead

Also a collaborator on its studies: Gilead Sciences, Pfizer and Hoffmann-La Roche.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Apr 10, 2001.

  1. Jun 1, 2006Phase 2 study in RecurrenceNovartis · NCT00333086 · 36 enrolled · Germany
  2. Sep 24, 2007Phase 3 study in Breast NeoplasmsNovartis · NCT00535418 · 35 enrolled
  3. Jan 24, 2008Sun Pharmaceutical Industries's first study: phase 3 study in InfertilityNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT00610077 · 55 enrolled · India
  4. Mar 30, 2008Viatris's first studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT00648154, NCT00648063
  5. May 29, 2008Phase 4 study in Breast NeoplasmsNovartis · NCT00688909 · 261 enrolled · United States
  6. Oct 28, 2010Phase 2 study in Breast NeoplasmsNovartis · NCT01231659 · 72 enrolled · Israel
  7. Jun 3, 2011Hikma Pharmaceuticals's first studies: 2 phase 1 studies in Breast NeoplasmsNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT01367652, NCT01367626
  8. Jun 13, 2011Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01372982, NCT01375452
  9. Oct 1, 2012Phase 2 study in Breast NeoplasmsNovartis · NCT01698918 · 202 enrolled · United States, Argentina, Brazil and more
  10. Feb 15, 2017Phase 2 study in Breast NeoplasmsNovartis · NCT03056755 · 383 enrolled · United States, Argentina, Belgium and more
  11. Jan 8, 2018rovi-pharmaceuticals-laboratories's first study: phase 1 study in HealthyNew to rovi-pharmaceuticals-laboratoriesrovi-pharmaceuticals-laboratories · NCT03401320 · 53 enrolled · Czechia
  12. Jan 29, 2018Phase 3 study in Breast NeoplasmsNovartis · NCT03439046 · 287 enrolled · Italy
  13. Apr 9, 2024Egymedicalpedia's first study: phase 1 study in Polycystic Ovary SyndromeNew to EgymedicalpediaEgymedicalpedia · NCT06367712 · 132 enrolled · Egypt
  14. Jul 7, 2024No phase study in Polycystic Ovary SyndromeEgymedicalpedia · NCT06507332 · 64 planned · Egypt

TargetBeta

CYP19A1 →read by rule
“Cytochrome P450 19A1 inhibitor”ChEMBL 37, by rule

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06507332Polycystic Ovary Syndrome · Egypt–RecruitingEgymedicalpediaSep 1, 202464
NCT06367712Polycystic Ovary Syndrome · Egypt1CompletedEgymedicalpediaNov 1, 2023132
NCT03439046Breast Neoplasms · Italy3TerminatedNovartisDec 11, 2023287
NCT03401320Healthy · Czechia1Completedrovi-pharmaceuticals-laboratoriesMay 17, 202453
NCT03056755Breast Neoplasms · United States, Argentina, Belgium and more2CompletedNovartisJun 14, 2021383
NCT01698918Breast Neoplasms · United States, Argentina, Brazil and more2CompletedNovartisDec 17, 2015202
NCT01375452Healthy1CompletedDr. Reddy's LaboratoriesMay 200836
NCT01372982Healthy1CompletedDr. Reddy's LaboratoriesJun 200836
NCT01367652Breast Neoplasms · United States1CompletedHikma PharmaceuticalsApr 200828
NCT01367626Breast Neoplasms · United States1CompletedHikma PharmaceuticalsApr 200828
NCT01231659Breast Neoplasms · Israel2CompletedNovartisNov 20, 201272
NCT00688909Breast Neoplasms · United States4CompletedNovartisJun 2009261
NCT00648154Healthy · United States1CompletedViatrisDec 200524
NCT00648063Healthy · United States1CompletedViatrisDec 200524
NCT00610077Infertility · India3CompletedSun Pharmaceutical IndustriesJul 200655
NCT00535418Breast Neoplasms3CompletedNovartisJul 200235
NCT00333086Recurrence · Germany2CompletedNovartisJun 200636
NCT00333047Breast Neoplasms · Germany3CompletedNovartis24
NCT00332852Breast Neoplasms · Germany3CompletedNovartisJul 2010655
NCT00332709Osteoporosis · Germany3CompletedNovartisAug 201083
NCT00330317Breast Neoplasms · United Kingdom3CompletedNovartisMar 2010300
NCT00329940Breast Neoplasms · France3CompletedNovartisJan 2008200
NCT00248170Breast Neoplasms · United States, Australia, Austria and more3CompletedNovartisSep 20144,172
NCT00247663Breast Neoplasms · Japan2CompletedNovartisDec 200517
NCT00247650Breast Neoplasms · Canada2CompletedNovartisMar 2007190
NCT00241046Breast Neoplasms4TerminatedNovartisMar 200513
NCT00240942Endometriosis2CompletedNovartisJun 200640
NCT00237224Breast Neoplasms · Mexico4CompletedNovartisFeb 200740
NCT00237211Breast Neoplasms · Japan2CompletedNovartisOct 200631
NCT00237198Breast Neoplasms · Japan2CompletedNovartisJul 200647
NCT00237133Breast Neoplasms · Brazil4CompletedNovartisJan 2009112
NCT00171847Breast Neoplasms · Germany4TerminatedNovartisOct 200893
NCT00171808Endometrial Neoplasms · Germany2CompletedNovartisMay 201026
NCT00171704Breast Neoplasms · Denmark, United Kingdom3CompletedNovartisMar 2011263
NCT00171340Bone Diseases, Metabolic · Argentina, Australia, Belgium and more3CompletedNovartisFeb 20101,065
NCT00171314Breast Neoplasms · Argentina, Belgium, France and more3CompletedNovartisNov 2010527
NCT00050011Breast Neoplasms · United States, Puerto Rico3CompletedNovartisJan 2009602
NCT00014638Breast Neoplasms · United States4CompletedNovartisMar 2002

How it is read

Names in the registry

  • “Letrozole”, 40 entries
  • “letrozole”, 6 entries
  • “Letrozole Tablets 2.5 mg”, 2 entries
  • “Arm C: Gedatolisib + Palbociclib + Letrozole”, 1 entry
  • “PF-07104091 + PF-07220060 + letrozole dose expansion”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.